Diligence memo · auto-generated · as of July 2, 2026
NephroDI Therapeutics, Inc.
NephroDI Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
NephroDI Therapeutics, Inc. operates in Pharmaceuticals, based in SEATTLE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NephroDI Therapeutics, Inc. has raised $3.6M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.0M on 2024-06-11.
Most recent recorded round closed around 2024-06-11.
Valuation (modeled)modeled
Provath models NephroDI Therapeutics, Inc. at approximately $9.8M (range $1.5M–$26M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.02× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era. Within the normal band (102% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 40 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 37% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.